Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Atreca Inc BCEL

Alternate Symbol(s):  COLUF

Atreca, Inc. is a clinical-stage biopharmaceutical company. The Company is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. It commenced clinical development of ATRC-101 with a Phase Ib clinical trial evaluating ATRC-101 as a monotherapy in patients with select solid tumors and opens a new cohort to evaluate ATRC-101 in combination with pembrolizumab, a PD-1 checkpoint inhibitor. It is also advancing additional product candidates using its discovery platform. Its oncology programs include APN-497444, an ADC against a tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.


PINL:BCEL - Post by User

Bullboard Posts
Comment by sweatmanon Jun 18, 2013 2:39pm
211 Views
Post# 21538493

RE: anyone here want too buy

RE: anyone here want too buy

This one is just one more company that the finance boys bought at the top. Their track record, on the surface at least, looks impeccable. Three high prices raises and all three puppy's sick in their beds and not rising to play fetch. I mentioned this a couple of weeks ago...that the share price needed to correct twenty or thirty cents from the raise price...and then it could be considered a buy. We are almost there, and seeing as it is a fool's game to try and buy at the absolute low and sell at the absolute high, we are within my comfort zone and *in my opinion*...this unproven mutt can be considered a buy. 

Bullboard Posts